MBMartin Bobek

Martin Bobek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Bobek has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety Monitoring of High-Risk Antibiotics Using Artificial Intelligence: A Narrative Review with Focus on Real-World Evidence

    by Mila Kostić, Marta Krpan, Paula Bulić, Martin Bobek, Jakov Kožić, Robert Likić

    High-risk antibiotics remain indispensable in contemporary infectious diseases practice, yet they account for a disproportionate share of preventable toxicity, therapeutic drug monitoring complexity, and antimicrobial stewardship workload. Vancomycin, aminoglycosides, colistin, linezolid, daptomycin, selected beta-lactams, and amphotericin B are particularly challenging because clinically relevant exposure-toxicity relationships coexist with marked inter-patient variability and fragmented post-marketing safety surveillance. Artificial intelligence and real-world evidence are increasingly proposed as complementary approaches to address these limitations, although the evidence base remains heterogeneous and predominantly retrospective. This narrative review synthesises literature from PubMed/MEDLINE, Scopus, and Web of Science published between 2019 and April 2026, supplemented by citation chaining and regulatory pharmacovigilance resources, with studies prioritised by implementation maturity, external validation status, and stewardship relevance. Current evidence indicates that artificial intelligence may improve safety monitoring when embedded within clinically rich data environments: machine learning models show promising discrimination for nephrotoxicity and haematological toxicity in vancomycin, colistin, and linezolid therapy; natural language processing may enhance adverse drug event extraction from clinical text; and Bayesian, model-informed tools already demonstrate clinical utility in vancomycin and aminoglycoside dosing. However, prospective implementation data remain sparse, external validation is uncommon, and evidence that these tools improve real-world antibiotic safety outcomes, as opposed to predictive discrimination alone, remains limited. Artificial intelligence-enabled antibiotic safety monitoring is therefore transitioning from methodological promise towards conditional clinical utility rather than proven benefit. Near-term value is most likely to arise from integration with therapeutic drug monitoring, antimicrobial stewardship, and pharmacology-led clinical review rather than autonomous decision-making, with clinical pharmacologists and stewardship teams leading local implementation, validation, and governance of these tools.

  • Open Access

    Ultra-Short DNA Fragments Undergo A-to-B Conformational Transitions Revealed by FTIR Spectroscopy

    by Kristina Serec, Josip Basić, Martin Bobek, Antonia Lovrenčić, Lucija Totić, Sanja Dolanski Babić

    Understanding interactions between cations and DNA is essential for elucidating the structural dynamics of this fundamental biomolecule. While B-DNA is well known to dominate in long genomic DNA under physiological ionic conditions, its stability in very short DNA fragments—particularly in dilute solutions and in crude oligonucleotide preparations—has remained largely unexplored. Previous spectroscopic studies have primarily focused on long DNA, highly purified oligonucleotides, or high-salt environments, where collective polyion effects dominate. In contrast, the present results demonstrate that even in the absence of chain overlap and under low-salt conditions, Mg2+ ions efficiently stabilize the B-form by screening phosphate–phosphate electrostatic repulsion at the intrachain level. The ability to induce an A-to-B transition in crude, ultra-short DNA fragments highlights the fundamental role of divalent counterions in governing DNA conformation and establishes a lower bound for the length scale at which B-DNA can be stabilized. These findings are particularly relevant for dilute biological systems, fragmented DNA samples, and analytical protocols where short DNA fragments and low ionic strength are unavoidable.